Development and characterization of Tinospora cordifolia extract-loaded SLNs for the treatment of autoimmune hepatitis

Solid Lipid Nanoparticles (SLNs) have emerged as promising drug delivery systems with the potential to enhance the therapeutic efficacy of bioactive compounds. In this study, T. Cordifolia extract-loaded SLNs were developed and characterized for their application in the treatment of autoimmune hepatitis. T. Cordifolia, known for its immunomodulatory and anti-inflammatory properties, was chosen as the active ingredient. The formulations were systematically evaluated for drug-excipient compatibility, particle size, zeta potential, drug loading efficiency, drug release kinetics, encapsulation efficiency, in-vitro release, and stability. The results indicated "No Change" in drug-excipient compatibility, ensuring the formulation's stability. The SLNs exhibited nanoscale particle sizes (159.30 nm to 172.12 nm) with narrow size distributions, facilitating consistent drug delivery. Negative zeta potentials (-28.28 mV to -35.44 mV) indicated colloidal stability. High drug loading efficiencies (up to 32.23%) and controlled drug release kinetics were observed, suggesting the potential for sustained and targeted drug delivery. Encapsulation efficiencies of up to 83.41% highlighted efficient drug loading within the SLNs. In-vitro release studies revealed that SLN2 and SLN4 exhibited superior drug release profiles compared to other formulations. These findings indicate the potential of these formulations for controlled drug delivery. In-vivo efficacy studies in murine models of autoimmune hepatitis are recommended to assess the therapeutic benefits of T. Cordifolia extract-loaded SLNs. Additionally, stability studies demonstrated the maintenance of critical parameters, such as particle size, zeta potential, and drug loading efficiency, under different storage conditions.